Codexis (NASDAQ:CDXS – Get Rating) had its price objective decreased by HC Wainwright from $25.00 to $15.00 in a note issued to investors on Monday, The Fly reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 148.76% from the stock’s current price.
CDXS has been the topic of a number of other research reports. Piper Sandler decreased their target price on shares of Codexis from $35.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, July 14th. Cowen dropped their target price on Codexis from $39.00 to $21.00 and set an “outperform” rating for the company in a report on Friday, July 15th. Cowen decreased their price target on Codexis from $39.00 to $21.00 in a research note on Friday, July 15th. Craig Hallum dropped their price objective on Codexis from $42.00 to $19.00 in a research note on Friday, July 15th. Finally, Benchmark set a $20.00 target price on shares of Codexis in a report on Tuesday, July 19th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.67.
Codexis Price Performance
Shares of CDXS opened at $6.03 on Monday. The firm has a market cap of $394.93 million, a P/E ratio of -12.56 and a beta of 1.49. Codexis has a 1 year low of $4.81 and a 1 year high of $41.91. The stock has a 50 day simple moving average of $6.16 and a two-hundred day simple moving average of $8.52.
Hedge Funds Weigh In On Codexis
A number of institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in shares of Codexis in the 1st quarter worth about $33,000. Lazard Asset Management LLC bought a new stake in Codexis during the second quarter worth about $66,000. US Bancorp DE grew its holdings in Codexis by 21.1% in the third quarter. US Bancorp DE now owns 14,586 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,540 shares during the period. SG Americas Securities LLC bought a new position in shares of Codexis during the second quarter valued at approximately $109,000. Finally, Strs Ohio lifted its holdings in shares of Codexis by 65.2% during the second quarter. Strs Ohio now owns 10,900 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 4,300 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.
- Get a free copy of the StockNews.com research report on Codexis (CDXS)
- The Cheesecake Factory Shows You Can Have It and Eat It Too
- 3 High Yields The Institutions Are Buying
- Two EV Stocks That Could Rally Into Year-End
- Can Activision Blizzard Rally Into Year End?
- 3 Old School Automakers Making Big EV Strides
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.